White Paper
IQVIA Pharma Deals Half-year Review of 2024
Sep 13, 2024

Discover the key trends and standout deals shaping the pharmaceutical industry in the first half of 2024, along with predictions for the rest of the year.


Key information provided:
  • Top M&A and partnership deals in H1 2024
  • Deal activity by therapeutic area and development phase
  • Deal value analysis of M&A, licensing and R&D deals
  • Deal activity rankings of the top pharmaceutical companies

Report key highlights:
  • Macroeconomic pressures and regulatory scrutiny led to a 20% drop in M&A deals from H1 2023 to H1 2024.
  • Licensing deal volume fell by 24%, but spending increased as quality took precedence over quantity.
  • Collaborative alliances remained below pre-pandemic levels, with an 8% decline from H1 2023 to H1 2024.
  • Oncology continued to dominate as the top therapy area for dealmaking, despite a reduction in overall deal volume.

Please fill in your details on the left to download the white paper.

Related solutions

Contact Us